Z2001
Zonisamide sodium salt
≥98% (HPLC), NO scavenger, powder
Synonym(s):
1,2-Benzisoxazole-3-methanesulfonamide sodium-potassium salt, Aleviatin sodium-potassium salt, Exceglan sodium-potassium salt, Excegram sodium-potassium salt
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C8H7N2NaO3S
CAS Number:
Molecular Weight:
234.21
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Product Name
Zonisamide sodium salt, ≥98% (HPLC), powder
Quality Level
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
H2O: >5 mg/mL
originator
Eisai
SMILES string
[Na]NS(=O)(=O)Cc1noc2ccccc12
InChI
1S/C8H7N2O3S.Na/c9-14(11,12)5-7-6-3-1-2-4-8(6)13-10-7;/h1-4H,5H2,(H-,9,11,12);/q-1;+1
InChI key
ZVBIRPKGWOVBLG-UHFFFAOYSA-N
Gene Information
Biochem/physiol Actions
Zonisamide sodium salt is an anti-epileptic and also scavenges nitric oxide (NO).
Zonisamide sodium salt is an anti-epileptic. It is effective in various animal epilepsy models and humans with both partial and generalized epileptic seizures. Zonisamide sodium salt also scavenges nitric oxide (NO).
Features and Benefits
This compound was developed by Eisai. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Gloves
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Related Content
Kyoung Heo et al.
Seizure, 21(3), 188-193 (2012-01-10)
To evaluate the efficacy and safety of adjunctive zonisamide (ZNS) therapy in Korean adults with uncontrolled partial epilepsy. Study patients had an average of at least one seizure per 4-week (averaged over a 12-week historical baseline) despite the use of
M E Choudhury et al.
European journal of pharmacology, 689(1-3), 72-80 (2012-06-05)
Zonisamide has been proven as an effective drug for the recovery of degenerating dopaminergic neurons in the animal models of Parkinson's disease. However, several lines of evidence have questioned the neuroprotective capacity of zonisamide in animal models of Parkinson's disease.
Michel Baulac et al.
The Lancet. Neurology, 11(7), 579-588 (2012-06-12)
Additional options are needed for monotherapy treatment of adults newly diagnosed with partial epilepsy. This trial compares the efficacy and tolerability of once-daily zonisamide with twice-daily controlled-release carbamazepine monotherapy for such patients. In this phase 3, randomised, double-blind, parallel-group, non-inferiority
Global Trade Item Number
| SKU | GTIN |
|---|---|
| Z2001-100MG | 04061832561530 |
| Z2001-10MG | 04061832561547 |